Clinical Trials
8 trialsNCT06043323 2026-05-06
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05757219 2026-03-31
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07042438 2026-03-05
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
City of Hope Medical Center
Phase 2 Recruiting
NCT05633615 2026-02-02
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Phase 2 Recruiting
NCT06213311 2026-01-14
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07254754 2025-11-28
LATE-R-GEL-23
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT06550141 2025-11-14
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Massachusetts General Hospital
Phase 2 Recruiting
NCT06826118 2025-02-13
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting